Moleculin Biotech Inc
MBRX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.36M
Close$
$7.19
13.6% downside
Current Fair Value
13.6% downsideOvervalued by 13.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.36 Million |
|---|---|
| Enterprise Value | $-4,751,820.00 |
| Earnings per Share | $-568.4 |
| Beta | 2 |
| Outstanding Shares | 284,036 |
Return
| Return on Equity | -261.73% |
|---|---|
| Return on Assets | -143.82% |
| Return on Invested Capital | -63.41% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 35.23 |
| Price to Sales | - |
| Price to Book Ratio | 0.21 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.13 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-1.46
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-8.87
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.27%▼ 0.42% |
|---|---|
| Total Invested | $518,510▲ 49.04% |
| Investors Holding | 18▼ 2.00% |
About Moleculin Biotech Inc
13 employees
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs a...